Daiwa Securities Group Inc. Acquires 535 Shares of Catalent, Inc. (NYSE:CTLT)

Daiwa Securities Group Inc. increased its holdings in Catalent, Inc. (NYSE:CTLT) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,380 shares of the company’s stock after purchasing an additional 535 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Catalent were worth $1,096,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Catalent by 1.8% during the 3rd quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after acquiring an additional 365,648 shares in the last quarter. Cadian Capital Management LP boosted its position in Catalent by 91.0% during the 3rd quarter. Cadian Capital Management LP now owns 5,304,784 shares of the company’s stock valued at $241,527,000 after acquiring an additional 2,526,750 shares in the last quarter. Barclays PLC boosted its position in Catalent by 41.7% during the 3rd quarter. Barclays PLC now owns 4,797,718 shares of the company’s stock valued at $218,440,000 after acquiring an additional 1,412,058 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Catalent by 65.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,483,494 shares of the company’s stock valued at $158,601,000 after acquiring an additional 1,384,313 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Catalent by 13.6% during the 3rd quarter. Northern Trust Corp now owns 2,160,603 shares of the company’s stock valued at $98,372,000 after acquiring an additional 258,482 shares in the last quarter.

Catalent Price Performance

Shares of NYSE CTLT opened at $55.92 on Thursday. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $60.20. The firm has a market cap of $10.12 billion, a P/E ratio of -8.22, a PEG ratio of 6.05 and a beta of 1.20. The company has a 50 day moving average of $56.78 and a 200 day moving average of $48.48. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Catalent’s revenue was down 10.2% on a year-over-year basis. As a group, research analysts expect that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CTLT has been the topic of several research reports. Barclays lifted their price objective on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, February 20th. UBS Group reiterated a “neutral” rating and set a $63.50 target price (up from $58.00) on shares of Catalent in a report on Tuesday, February 6th. StockNews.com started coverage on shares of Catalent in a report on Friday, April 19th. They set a “sell” rating for the company. Finally, Stephens reiterated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.46.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.